Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;28(4):841-850.
doi: 10.3350/cmh.2022.0239. Epub 2022 Sep 19.

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Michael H Le  1   2 , Yee Hui Yeo  1   3 , Biyao Zou  1   4 , Scott Barnet  1 , Linda Henry  1 , Ramsey Cheung  1   5 , Mindie H Nguyen  1   4
Affiliations

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Michael H Le et al. Clin Mol Hepatol. 2022 Oct.

Abstract

Background/aims: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD. Here, we used the Bayesian approach to forecast the prevalence of NAFLD through the year 2040.

Methods: Prevalence data from 245 articles involving 2,699,627 persons were used with a hierarchical Bayesian approach to forecast the prevalence of NAFLD through 2040. Subgroup analyses were performed for age, gender, presence of metabolic syndrome, region, and smoking status. Sensitivity analysis was conducted for clinical setting and study quality.

Results: The forecasted 2040 prevalence was 55.7%, a three-fold increase since 1990 and a 43.2% increase from the 2020 prevalence of 38.9%. The estimated average yearly increase since 2020 was 2.16%. For those aged <50 years and ≥50 years, the 2040 prevalence were not significantly different (56.7% vs. 61.5%, P=0.52). There was a significant difference in 2040 prevalence by sex (males: 60% vs. 50%) but the trend was steeper for females (annual percentage change: 2.5% vs. 1.5%, P=0.025). There was no difference in trends overtime by region (P=0.48). The increase rate was significantly higher in those without metabolic syndrome (3.8% vs. 0.84%, P=0.003) and smokers (1.4% vs. 1.1%, P=0.011). There was no difference by clinical/community setting (P=0.491) or study quality (P=0.85).

Conclusion: By 2040, over half the adult population is forecasted to have NAFLD. The largest increases are expected to occur in women, smokers, and those without metabolic syndrome. Intensified efforts are needed to raise awareness of NAFLD and to determine long-term solutions addressing the driving factors of the disease.

Keywords: Metabolic syndrome; Smoking; Trends; Women.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

MHN: Research funding: Pfizer, Enanta, Gilead, CurveBio, Exact Sciences, Helio Health, Glycotest, National Cancer Institute, B.K. Kee Foundation, Vir Biotech; Consulting: Gilead, Intercept, GSK, Exact Science, Novartis, Janssen, Bayer

RC: Research funding: Gilead, Siemens Healthineer

All other authors do not have any conflict of interest to declare.

Figures

Figure 1.
Figure 1.
Overall forecast of global nonalcoholic fatty liver disease prevalence.
Figure 2.
Figure 2.
Forecast of nonalcoholic fatty liver disease prevalence by (A) age and (B) sex. P-values compare the rate of increase between subgroups via linear regression.
Figure 3.
Figure 3.
Forecast of nonalcoholic fatty liver disease (NAFLD) prevalence* for North America, Europe, and Asia. P-values compare the rate of increase between subgroups via linear regression. *Based on past trend of ultrasound diagnosed prevalence of NAFLD. North America subgroup included studies that used FLI to diagnose NAFLD. Data were insufficient to perform forecasting for Africa and South America.
Figure 4.
Figure 4.
Forecast of nonalcoholic fatty liver disease prevalence by the presence of (A) metabolic syndrome or (B) cigarette smoking. P-values compare the rate of increase between subgroups via linear regression.
None
See this image and copyright information in PMC

References

    1. Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD) Endocr Pract. 2022;28:528–562. - PubMed
    1. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021 Dec 7; doi: 10.1016/j.cgh.2021.12.002. - PubMed
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. - PubMed
    1. Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009-2019. J Hepatol. 2021;75:795–809. - PubMed
    1. Li J, Ha A, Rui F, Zou B, Yang H, Xue Q, et al. Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021. Aliment Pharmacol Ther. 2022;56:396–406. - PubMed